Clinics in haematology最新文献

Platelet disorders 血小板疾病

Clinics in haematology Pub Date : 2018-08-01 DOI: 10.1093/med/9780199568741.003.0282

N. Curry, R. Alikhan

引用次数: 0

Cell Culture Techniques 细胞培养技术

Clinics in haematology Pub Date : 2011-07-01 DOI: 10.1007/978-1-61779-077-5

Swati Rauthan

引用次数: 24

The role of colony stimulating factors in leukaemogenesis. 集落刺激因子在白血病发生中的作用。

Clinics in haematology Pub Date : 1986-11-01

J D Griffin, D C Young

引用次数: 0

Classification of the myelodysplastic syndromes. 骨髓增生异常综合征的分类。

Clinics in haematology Pub Date : 1986-11-01 DOI: 10.1007/978-3-642-75952-9_1

J. Bennett

引用次数: 30

The treatment of myelodysplastic syndromes. 骨髓增生异常综合征的治疗。

Clinics in haematology Pub Date : 1986-11-01

D R Spriggs, R M Stone, D W Kufe

{"title":"The treatment of myelodysplastic syndromes.","authors":"D R Spriggs, R M Stone, D W Kufe","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The available data fail to support a standard therapy for MDS. Any therapy should therefore, include participation in a well designed clinical trial. The MDS include patients with a variety of prognoses. Since most studies show that death from infection and bleeding are more likely than progression to frank leukaemia, attention to supportive care is crucial for all patients with MDS. Some patients with MDS may be successfully supported with transfusions and observation for prolonged periods. Patients with significant comorbid disease or patients without increased marrow myeloblasts are good candidates for this conservative approach. Conversely, young patients have a better likelihood of benefit from aggressive therapy, and intensive chemotherapy or allogenic bone marrow transplantation should be considered. Patients with preleukaemia related to prior cytotoxic therapy are another poor prognosis group for whom aggressive therapy may be the best alternative. Therapy with low-dose ara-C or other differentiating agents should be considered investigational and unproven until comparative trials can demonstrate a definitive survival advantage. In addition to comparative trials, innovative clinical studies are needed to address differentiation as an in vivo mechanism of action and its importance in MDS therapy.</p>","PeriodicalId":75718,"journal":{"name":"Clinics in haematology","volume":"15 4","pages":"1081-107"},"PeriodicalIF":0.0,"publicationDate":"1986-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14674112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myelodysplastic syndromes: natural history and features of prognostic importance. 骨髓增生异常综合征:自然史和预后重要性的特征。

Clinics in haematology Pub Date : 1986-11-01

G J Mufti, D A Galton

引用次数: 0

5q- and disordered haematopoiesis. 5q-和紊乱的造血。

Clinics in haematology Pub Date : 1986-11-01

H F Bunn

引用次数: 0

Chromosome abnormalities in the myelodysplastic syndromes. 骨髓增生异常综合征中的染色体异常。

Clinics in haematology Pub Date : 1986-11-01

S Heim, F Mitelman